Value
4.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 4.0 |
EWTX · Why this verdict
Why Edgewise Therapeutics (EWTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Edgewise Therapeutics offers approximately 14% upside to the near-term price target with a roughly 2-to-1 favorable risk/reward ratio, and analyst consensus implies approximately 31% upside; however, quality metrics — reflecting cash-burning operations and a pipeline concentrated in just two clinical programs — fall well below the minimum threshold required for a position, making the setup a watch-and-validate rather than an actionable entry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analyst consensus carries approximately 31% implied upside above current levels, driven by pipeline optionality in the two lead programs; if either program generates a favorable clinical data readout, the stock could close a significant portion of that discount rapidly. Sentiment breakdown | Analyst consensus maintains price targets implying greater than 20% upside for 4 consecutive quarters, reflecting sustained confidence in the pipeline's advancement. | →Stable |
| CounterA 14% short interest and an elevated put/call ratio of 1.61 represent a substantial market conviction against the thesis, reflecting a well-informed bearish view that could quickly suppress any analyst-target-driven upside if clinical updates disappoint. | ||
A short interest of 14% of float indicates that a meaningful portion of the market is actively positioned against the stock, reflecting skepticism about pipeline timing, cash sustainability, or the clinical read-through probability — a level of bearish conviction that represents a real near-term overhang. Key risks | Short interest falls below 8% over the next 12 months as positive clinical catalysts reduce bearish conviction and incremental buying absorbs existing shorts. | →Stable |
| CounterAn elevated short position at 14% also represents a source of potential upside acceleration if positive clinical data surprises the market, as short-covering demand would compound organic buyer interest. | ||
The company's entire clinical and commercial optionality rests on two programs — sevasemten and EDG-7500 — meaning any late-stage failure or unexpected clinical setback would leave the portfolio substantially impaired with no diversification buffer. Bear case | At least one of the two lead programs advances to a next-stage clinical milestone within 12 months, providing a concrete de-risking event that reduces dependence on both assets performing simultaneously. | →Stable |
| CounterThe analyst community assigns approximately 31% price-target upside above current levels despite the two-asset concentration, suggesting the market views both programs as carrying sufficient optionality to justify the current valuation without requiring diversification. | ||
The company is pre-revenue with negative free cash flow at every reporting level and quality metrics well below the minimum threshold at 1.5 versus a floor of 4.0, placing near-term viability in direct dependence on continued capital market access and timely clinical progress. Quality breakdown | Quarterly earnings losses narrow to within -$0.35 or better over the next 12 months, indicating the cash burn trajectory is decelerating and runway is being preserved. | →Stable |
| CounterThree of the last four quarters produced positive earnings surprises versus estimates, and a Piotroski F-Score of 4 out of 9 — while below ideal — does not signal imminent financial distress for a pre-revenue clinical-stage company with an active pipeline. | ||
Analyst consensus carries approximately 31% implied upside above current levels, driven by pipeline optionality in the two lead programs; if either program generates a favorable clinical data readout, the stock could close a significant portion of that discount rapidly.
→StableSentiment breakdown
- Expectation
- Analyst consensus maintains price targets implying greater than 20% upside for 4 consecutive quarters, reflecting sustained confidence in the pipeline's advancement.
CounterA 14% short interest and an elevated put/call ratio of 1.61 represent a substantial market conviction against the thesis, reflecting a well-informed bearish view that could quickly suppress any analyst-target-driven upside if clinical updates disappoint.
A short interest of 14% of float indicates that a meaningful portion of the market is actively positioned against the stock, reflecting skepticism about pipeline timing, cash sustainability, or the clinical read-through probability — a level of bearish conviction that represents a real near-term overhang.
→StableKey risks
- Expectation
- Short interest falls below 8% over the next 12 months as positive clinical catalysts reduce bearish conviction and incremental buying absorbs existing shorts.
CounterAn elevated short position at 14% also represents a source of potential upside acceleration if positive clinical data surprises the market, as short-covering demand would compound organic buyer interest.
The company's entire clinical and commercial optionality rests on two programs — sevasemten and EDG-7500 — meaning any late-stage failure or unexpected clinical setback would leave the portfolio substantially impaired with no diversification buffer.
→StableBear case
- Expectation
- At least one of the two lead programs advances to a next-stage clinical milestone within 12 months, providing a concrete de-risking event that reduces dependence on both assets performing simultaneously.
CounterThe analyst community assigns approximately 31% price-target upside above current levels despite the two-asset concentration, suggesting the market views both programs as carrying sufficient optionality to justify the current valuation without requiring diversification.
The company is pre-revenue with negative free cash flow at every reporting level and quality metrics well below the minimum threshold at 1.5 versus a floor of 4.0, placing near-term viability in direct dependence on continued capital market access and timely clinical progress.
→StableQuality breakdown
- Expectation
- Quarterly earnings losses narrow to within -$0.35 or better over the next 12 months, indicating the cash burn trajectory is decelerating and runway is being preserved.
CounterThree of the last four quarters produced positive earnings surprises versus estimates, and a Piotroski F-Score of 4 out of 9 — while below ideal — does not signal imminent financial distress for a pre-revenue clinical-stage company with an active pipeline.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.1 |
| Price target | 7.0 |
| erm sentiment | 5.0 |
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $4,210,201 (0.093% of mkt cap)
Peer rank
4.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 4.0 |
| growth rank | 5.0 |
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 1.4 |
| 52w position | 9.2 |
Risk (lower is worse)
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.8 |
| days to cover | 1.6 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 6.4 |
- ▸Elevated put/call: 2.38
- ▸High IV: 87%
- ▸Above max pain $25
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 5.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.8>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.0=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.03
Upside
-0.4%
Downside
15.0%
Sizing output
AVOID
SetupBREAKOUT — Golden cross, above all MAs, RSI 64, MACD bullish
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $4.6B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Momentum at 6.8 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.0=NEGATIVE.
The strongest dimensions are Momentum at 6.8, Sentiment at 6.5, and Catalyst at 5.4; the weakest are Quality at 1.5, Risk (lower is worse) at 3.0, and Technical at 3.5. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.03 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company's entire clinical and commercial optionality rests on two programs — sevasemten and EDG-7500 — meaning any late-stage failure or unexpected clinical setback would leave the portfolio substantially impaired with no diversification buffer.
Trip ifTotal active clinical programs grows to 3 or more as disclosed in 2 consecutive quarterly filings.
- P2The company is pre-revenue with negative free cash flow at every reporting level and quality metrics well below the minimum threshold at 1.5 versus a floor of 4.0, placing near-term viability in direct dependence on continued capital market access and timely clinical progress.
Trip ifQuarterly EPS rises above -$0.35 for 2 consecutive quarters, signaling the cash burn rate is narrowing toward sustainability.
- P3Analyst consensus carries approximately 31% implied upside above current levels, driven by pipeline optionality in the two lead programs; if either program generates a favorable clinical data readout, the stock could close a significant portion of that discount rapidly.
Trip ifAnalyst consensus price target falls to imply less than 15% upside for 2 consecutive quarters.
- P4A short interest of 14% of float indicates that a meaningful portion of the market is actively positioned against the stock, reflecting skepticism about pipeline timing, cash sustainability, or the clinical read-through probability — a level of bearish conviction that represents a real near-term overhang.
Trip ifShort interest falls below 8% of float for 2 consecutive monthly readings.